Add BrightSurf on Google Email

Small molecule targets Achilles' Heel of AML, kills cancer cells

Researchers at Cincinnati Children's Hospital Medical Center have identified a protein crucial to AML cell survival and found a small molecule that blocks its function, killing cancer cells in lab dishes and mouse models. This potential breakthrough could lead to novel therapies for AML and other conditions.

SourceCincinnati Children's Hospital Medical Center·JournalScience Translational Medicine·TypeExperimental study·DateMar 16, 2022

Scientists uncover a new approach for treating aggressive cancer

Researchers at UNC Lineberger Comprehensive Cancer Center have developed a new therapeutic approach using a small-molecule inhibitor of the chromatin-modulatory enzyme EZH2 to target aggressive cancer cells. The treatment also targets cMyc, a prominent cancer-causing factor, and shows profound tumor killing effects.

SourceUNC Lineberger Comprehensive Cancer Center·JournalNature Cell Biology·TypeExperimental study·DateFeb 24, 2022

T-cell responses may help predict protection against SARS-CoV-2 infection in individuals with and without cancer

New study reveals that T-cell responses against the SARS-CoV-2 spike protein can predict protection against infection. In healthy individuals, T cells with a specific cytokine profile offered immunity against COVID-19. In contrast, cancer patients showed lower T-cell responses and increased susceptibility to infection.

SourceAmerican Association for Cancer Research·JournalCancer Discovery·DateFeb 18, 2022

New detailed immune-profiling method uses only DNA from blood

A novel immune-profiling method can return detailed immune cell type proportions using only DNA from blood, potentially allowing for individualized prediction of outcomes in immunotherapy patients. This approach offers the opportunity to ask and answer questions about the immune system in health and disease.

SourceDartmouth Health·JournalNature Communications·TypeExperimental study·DateFeb 9, 2022

Study of Penn patients with decade-long leukemia remissions after Car T cell therapy reveals new details about persistence of personalized “living drug” cells

Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.

SourceUniversity of Pennsylvania School of Medicine·JournalNature·TypeData/statistical analysis·DateFeb 2, 2022

How a contagious cancer spread among clams

Researchers confirm contagious blood cancer can jump between marine clam species, with evidence suggesting human activities may contribute to the spread. The discovery highlights the potential ecological threat posed by these diseases and emphasizes the need for further studies to monitor pathogens.

SourceeLife·JournaleLife·DateJan 18, 2022

A donation that could help cure blood cancer

A study published in Leukemia found that cord blood transplantation (CBT) was more effective than matched related donor transplantation (MRDT) for patients with refractory and relapsed acute myeloid leukemia (R/R AML). The study compared the survival rates of 1,738 CBT-treated patients with those of 713 MRDT-treated patients, revealing...

SourceOsaka University·JournalLeukemia·TypeObservational study·DateJan 5, 2022

Research published in AACR journal and presented at ASH identifies potential approach to mitigate CAR T-cell therapy toxicity

A novel approach may reduce the serious adverse effect of cytokine release syndrome associated with chimeric antigen receptor (CAR) T-cell therapy. Supressing interferon gamma (IFNγ) appears to prevent activation of macrophages and other immune cells that drive the syndrome without impacting CAR T-cell efficacy.

SourceAmerican Association for Cancer Research·JournalBlood Cancer Discovery·DateDec 15, 2021

Specific metabolic dependencies of cancer cells revealed by perturbation with tailored chemical library offer new therapeutic possibilities

Researchers identified specific metabolic vulnerabilities in leukemia cell lines, including sensitivity to PI3K and fatty acid synthase inhibitors. The study highlights the potential for targeted cancer therapy by exploiting these dependencies.

Chemotherapy fails for some blood cancer patients because of crucial gene mutations, finds study by NTU Singapore and Singapore General Hospital

A recent study by NTU Singapore and Singapore General Hospital found that mutations in the DDX3X gene are responsible for chemotherapy resistance in some blood cancer patients. The study also discovered that STAT inhibitors can effectively kill lymphoma cells with DDX3X mutations, providing hope for new treatment options.

SourceNanyang Technological University·JournalMolecular Cancer·TypeExperimental study·DateDec 6, 2021

Functional precision medicine using drug sensitivity testing enables tailoring of therapy for leukemia patients

A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.

SourceUniversity of Helsinki·JournalCancer Discovery·DateNov 17, 2021

New study in JNCCN finds disturbing lack of key leukemia medication

A recent study published in JNCCN found that only 31% of hospitals have immediate availability of all-trans retinoic acid (ATRA), a crucial blood cancer medication. This medication is essential for treating acute promyelocytic leukemia, which has a better prognosis when treated appropriately. The lack of ATRA availability poses a signi...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeSurvey·DateNov 16, 2021

New technique may lead to safer stem cell transplants

Researchers have developed a new method of stem cell transplantation that does not require chemotherapy or radiation. The approach uses immunotherapeutic drugs to eliminate cancer cells and prevent immune rejection. This technique has the potential to be curative for blood cancers and treat other diseases like sickle cell anemia.

SourceWashU Medicine·JournalJournal of Clinical Investigation·DateNov 11, 2021

Treatment enhances anti-leukemia effect of bone marrow transplant, reduces recurrence, study finds

Researchers found that adding interferon to bone marrow transplant significantly reduced leukemia relapse among high-risk patients, improving outcomes. The study suggests a potential new strategy for treating advanced acute myeloid leukemia, with further research needed to confirm the findings.

SourceMichigan Medicine - University of Michigan·JournalBlood Advances·TypeExperimental study·DateOct 20, 2021

Researchers identify new drug target for blood cancer, potentially solid tumors

Researchers have discovered a new drug target for myelodysplastic syndrome (MDS) and other hematologic malignancies, which are sensitive to MEK inhibitors. The study found that mutations affecting RNA splicing alter cells to develop MDS and solid tumors, providing a potential new approach to treating this rare blood cancer.

Researchers at CNIO and 12 de Octubre Hospital prove efficacy of new immunotherapy for multiple myeloma

Researchers at CNIO and 12 de Octubre Hospital have developed a new cancer treatment called CAR-NK-cell immunotherapy, which uses natural killer cells to target cancerous cells. The treatment has shown promising results in mice with multiple myeloma, with 25% of treated mice remaining disease-free.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalBlood Cancer Journal·TypeExperimental study·DateOct 6, 2021

Scientists from Pusan National University emphasize the health benefits of ginseng

Researchers from Pusan National University have compiled a comprehensive review of ginsenosides, the main component of ginseng, which can prevent inflammation, diabetes, and cancer. The study provides insights into how to improve ginsenoside production through chemical and enzymatic treatments, as well as microbial action.

SourcePusan National University·JournalCritical Reviews in Food Science and Nutrition·TypeLiterature review·DateSep 15, 2021

USC study identifies new risk factor for most common childhood cancer, acute lymphoblastic leukemia (ALL)

Children genetically predisposed to overproduce lymphocytes in relation to other white blood cells are at higher risk of developing ALL, according to a new USC study. The research found that the ratio of lymphocytes to other key blood cells is significant in predicting leukemia risk.

SourceKeck School of Medicine of USC·JournalAmerican Journal of Human Genetics·TypeObservational study·DateSep 8, 2021

Hopkins med news update

Researchers found that remnant cholesterol levels above 24 micrograms per deciliter were associated with a 40-50% higher risk of major heart disease or stroke. The study suggests using remnant cholesterol as an additional metric for predicting cardiovascular disease and stroke risk, in addition to LDL cholesterol levels.

SourceJohns Hopkins Medicine·JournalEuropean Heart Journal·DateSep 7, 2021

Researchers from Tel Aviv University prove for the first time that silent mutations can predict the development of cancer cells

Silent mutations, which don't change protein sequences, hold diagnostic value in predicting cancer types and patient survival. The study analyzed over 10,000 cancer genomes and found that combining information from silent and non-silent mutations improved classification and prognostication up to 17% and 5%, respectively.

SourceTel-Aviv University·Journalnpj Genomic Medicine·DateAug 31, 2021

Teaching an old dog new tricks: An existing drug opens new possibilities for treating child leukemia

A study from Linköping University found that the tumour-inhibiting gene TET2 is silenced in most cases of acute lymphoblastic leukemia (ALL) in children. The gene can be reactivated by treatment with an existing drug, 5-azacytidine, suggesting a targeted therapy for ALL in children.

SourceLinköping University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateAug 24, 2021